Distinct lung cell signatures define the temporal evolution of diffuse alveolar damage in fatal COVID-19.
Saved in:
| Title: | Distinct lung cell signatures define the temporal evolution of diffuse alveolar damage in fatal COVID-19. |
|---|---|
| Authors: | Milross L; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK., Hunter B; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK., McDonald D; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK., Merces G; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK., Thomson A; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK., Hilkens CMU; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK., Wills J; Department of Veterinary Medicine, University of Cambridge, Cambridge, UK., Rees P; Department of Biomedical Engineering, Swansea University, Wales, UK; Imaging Platform, Broad Institute of MIT and Harvard, 415 Main Street, Boston, Cambridge, MA, USA., Jiwa K; Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Cooper N; Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Majo J; Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Ashwin H; York Biomedical Research Institute, Hull York Medical School, University of York, York, UK., Duncan CJA; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Kaye PM; York Biomedical Research Institute, Hull York Medical School, University of York, York, UK., Bayraktar OA; Wellcome Sanger Institute, Hinxton, Cambridge, UK., Filby A; Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK. Electronic address: andrew.filby@newcastle.ac.uk., Fisher AJ; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Institute of Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: a.j.fisher@newcastle.ac.uk. |
| Source: | EBioMedicine [EBioMedicine] 2024 Jan; Vol. 99, pp. 104945. Date of Electronic Publication: 2023 Dec 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
